The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms

Journal of Vascular Surgery

Volumn 46, Issue 4, 2007, Pages 682-686

  Hobbs, Simon D ^a   Haggart, Paul ^a   Fegan, Chris ^a   Bradbury, Andrew W ^a   Adam, Donald J ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANEURYSM SURGERY; AORTA CLAMPING; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTIVE SURGERY; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; CARBOXYPEPTIDASE U; FACTOR XA; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34548832726     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.05.057     Document Type: Article

References (16)

1. Adam D.J., Ludlam C.A., Ruckley C.V., and Bradbury A.W. Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg 30 (1999) 641-650
2. Adam D.J., Haggart P.C., Ludlam C.A., and Bradbury A.W. Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair. Ann Vasc Surg 18 (2004) 572-577
3. Garcia-Fernandez N., Lavilla F.J., Rocha E., and Purroy A. Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy. J Nephrol 13 (2000) 282-289
4. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 31 (2003) S213-S220
5. Gando S. Tissue factor in trauma and organ dysfunction. Semin Thromb Hemost 32 (2006) 48-53
6. Laterre P.F., Wittebole X., and Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost 32 (2006) 71-76
7. Yamazumi K., Ojiro M., Okumura H., and Aikou T. An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. Am J Surg 175 (1998) 297-301
8. Nomura F., Ihara A., Yoshitatsu M., Tamura K., Katayama A., and Ihara K. Relationship between coagulation cascade, cytokine, adhesion molecule and aortic aneurysm. Eur J Cardiothorac Surg 23 (2003) 1034-1038 discussion 1038-9
9. Gando S., Nanzaki S., Morimoto Y., Kobayashi S., and Kemmotsu O. Tissue factor and tissue factor pathway inhibitor levels during and after cardiopulmonary resuscitation. Thromb Res 96 (1999) 107-113
10. Gando S., Nanzaki S., Morimoto Y., Ishitani T., and Kemmotsu O. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med 29 (2001) 262-266
11. Haggart P.C., Adam D.J., Ludman P.F., Ludman C.A., and Bradbury A.W. Myocardial injury and systemic fibrinolysis in patients undergoing repair of ruptured abdominal aortic aneurysm. European Journal of Vascular & Endovascular Surgery 21 (2001) 529-534
12. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2003) 375-381
13. Paola Cellai A., Antonucci E., Alessandrello Liotta A., Fedi S., Marcucci R., Falciani M., Giglioli C., Abbate R., and Prisco D. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 118 (2006) 495-500
14. Zeerleder S., Schroeder V., Hack C.E., Kohler H.P., and Wuillemin W.A. TAFI and PAI-1 levels in human sepsis. Thromb Res 118 (2006) 205-212
15. Chen C.C., Lee K.D., Gau J.P., Yu Y.B., You J.Y., Lee S.C., et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 84 (2005) 675-680
16. Levi M., van der Poll T., and ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 32 (2006) 33-39